A University of Queensland researcher is part of a national project which has received $1 million funding to discover the proteins that cause multiple sclerosis (MS).
Dr Judith Greer, a senior research fellow in UQ’s Centre for Clinical Research, is participating in the research project – the first of its kind in Australia and one of the first of its kind in the world.
More than 2.5 million people worldwide have MS, with the disease costing the Australian community alone an estimated $2 billion each year. Despite considerable research efforts so far, there are few effective treatments for MS.
The new research project will receive funding of $1 million over four years, starting this year, under the Australian Research Council's Linkage Projects funding scheme and from MS Research Australia (MSRA), the research arm of MS Australia.
The research is a major national MS collaboration between three Australian universities and the Sir Charles Gairdner Hospital. The collaboration includes:
• Professor Shaun McColl, University of Adelaide (SA) (lead investigator)
• Dr Judith Greer, University of Queensland (QLD)
• Professor Claude Bernard, Monash University (VIC)
• Prof Bill Carroll, Sir Charles Gairdner Hospital (WA)
• Dr Peter Hoffmann, University of Adelaide (SA)
• Professor Ian Smith, Monash University (VIC)
Dr Greer, who is an immunologist with a strong interest in the nervous system and autoimmune diseases affecting the nervous system, has high expectations for this project.
“Interactions between proteins and the immune system play a defining role in each stage of MS,” she said.
“My group is particularly interested in how these interactions lead to the development of damage to specific parts of the brain and spinal cord in MS.
“If we can identify the set of proteins influencing the onset and development of the disease, it might be then possible to develop targeted treatments.”
"With MS, there are a number of major stages that occur in the disease, including activation and remission," says Professor Shaun McColl, Deputy Head of the School of Molecular & Biomedical Science at the University of Adelaide.
"At each of these major stages, certain genes are activated. Those genes express proteins, and we believe these could have the effect of switching the disease on and off. If we can discover the key proteins and their roles in the development of MS, we could go a long way towards finding potential treatments or cures for the condition," he says.
The area of research involved in discovering such proteins is known as proteomics.
Mr Jeremy Wright, Executive Director of MS Research Australia, says: "This is a natural step for MSRA to help researchers make important new discoveries that will translate into real outcomes for people with MS. Together with the ARC we are investing $1 million into this promising new area for MS research."
Facts about MS
Multiple sclerosis is an autoimmune disease in which the body's own immune cells attack a person's central nervous system. MS affects the ability of nerve cells in the brain and spinal cord to communicate with each other.
More than 2.5 million people around the world have MS. This includes around 20,000 Australians.
Three out of every four people diagnosed are women.
MS is the most common neurological disease in young adults. It often strikes when a person is at their most active, usually in their early 20s, with increasing professional, social and/or family responsibilities.
The total financial cost annually of MS to the Australian community is estimated to be nearly $2 billion.
Multiple Sclerosis Research Australia was set up in 2004 by MS Australia to lift the MS research effort by raising funds and steering national research based on five interrelated platforms.
It advances knowledge of treatments, a cause and cure for MS by targeting research in which Australia can lead the world.
For more information visit: www.msra.org.au
Media: Dr Judith Greer, telephone 07 3346 6018 or email: j.greer@uq.edu.au
